Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
    • Philanthropic Consulting
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report

BY Benzinga
— 7:19 AM ET 06/15/2022
  • Moderna Inc's NASDAQ:MRNA COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17.
  • Reuters reported that there is limited chance for a significant immediate demand for the Moderna shots for 6- to 17-year-olds. 
  • It cited Pfizer Inc NYSE:PFE / BioNTech SE's NASDAQ:BNTX vaccine authorization for children aged 5 to 11 in October and approval for teenagers in a couple of months.
  • According to CDC, just 30% of kids between 5 to 11 years and 60% of 12 -17-year-olds are fully vaccinated in the U.S.
  • Children ages 6 to 11 would receive smaller 50 microgram shots, while teens ages 12 to 17 would receive the same dosage as adults at 100 micrograms.
  • The FDA is likely to authorize the Moderna vaccine for ages 6-17 soon. The CDC also needs to recommend the vaccine's use. A committee of its advisers is scheduled to meet Friday and Saturday.
  • There have been concerns that the Moderna vaccine is associated with a higher risk of heart inflammation than the Pfizer/BioNTech vaccine.
  • Price Action: MRNA shares closed 3.78% higher at $121.56 on Tuesday.
  • Photo by mufidpwt via Pixaby

More BNTX News

  • EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters
    Benzinga - 1:28 PM ET 06/14/2022
  • Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters
    Benzinga - 1:11 PM ET 06/14/2022
  • 5 Biotech Stocks To Watch During The Week Of June 13
    Benzinga - 8:25 AM ET 06/13/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close